The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
General Updates | Evaluating the role of autoSCT vs CAR-T in LBCL: expert insights & advice for community oncologists
In this discussion, experts Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Evandro Bezerra, MD, Cleveland Clinic, Cleveland, OH, and Andrew Jallouk, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, discuss the role of autologous stem cell transplantation (autoSCT) versus CAR-T therapy in large B-cell lymphoma (LBCL). They share insights into how the treatment landscape has changed following the introduction of CAR T-cells, highlighting findings from relevant clinical trials, including ZUMA-7 (NCT03391466), BELINDA (NCT03570892), and TRANSFORM (NCT03575351). The experts also share examples from their own clinical practice and advice for community oncologists. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
